The malignant signature gene of cancer-associated fibroblasts serves as a potential prognostic biomarker for colon adenocarcinoma patients
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study identifies FNDC5 as a key gene linked to cancer-associated fibroblast malignancy in colon adenocarcinoma (COAD). FNDC5 shows prognostic value and impacts cancer cell behavior, suggesting it as a potential therapeutic target for COAD.
Area Of Science
- Oncology
- Genomics
- Bioinformatics
Background
- Colon adenocarcinoma (COAD) is a prevalent cancer.
- Cancer-associated fibroblasts (CAFs) influence tumor progression, but their role in COAD requires further elucidation.
- This study investigates gene markers associated with CAF malignancy in COAD using single-cell RNA sequencing (scRNA-seq).
Purpose Of The Study
- To identify and validate gene markers associated with the malignancy of cancer-associated fibroblasts (CAFs) in colon adenocarcinoma (COAD).
- To develop a prognostic risk model for COAD based on CAF-related genes.
- To evaluate FNDC5 as a potential therapeutic target for COAD.
Main Methods
- Analysis of 8,911 cells from normal and tumor samples using scRNA-seq.
- Cell communication, copy number variation (CNV), and pseudotime trajectory analyses were performed.
- LASSO regression, Cox regression, nomogram construction, and in vitro assays were utilized to identify and validate prognostic genes, including FNDC5.
Main Results
- Six distinct cell types were identified; cell communication pathways were elucidated.
- CAFs were classified into three malignancy groups via CNV analysis.
- FNDC5 was identified as an independent prognostic gene associated with T stage and metastasis, and its knockdown affected cancer cell proliferation, migration, and invasion.
Conclusions
- A novel risk model for CAF malignancy-related genes in COAD was developed.
- FNDC5 was identified as a potential therapeutic target for colon adenocarcinoma.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...